Takeda Pharmaceutical Co. reported revenues of JPY 3,212.9 billion for the nine-month period ending December 31, 2023, a 4.6% increase from the previous year. The significant drop in net profit to JPY 147.2 billion (down 48.5%) is attributed to generic erosion and intensified competition, especially in Oncology and Neuroscience segments.